TD Asset Management Inc Buys 9,500 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

TD Asset Management Inc boosted its stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 172.7% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 15,000 shares of the specialty pharmaceutical company’s stock after acquiring an additional 9,500 shares during the period. TD Asset Management Inc’s holdings in Collegium Pharmaceutical were worth $483,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in COLL. Gladius Capital Management LP bought a new stake in Collegium Pharmaceutical in the second quarter valued at approximately $32,000. Principal Securities Inc. bought a new stake in Collegium Pharmaceutical in the fourth quarter valued at approximately $40,000. nVerses Capital LLC boosted its holdings in Collegium Pharmaceutical by 1,600.0% in the second quarter. nVerses Capital LLC now owns 1,700 shares of the specialty pharmaceutical company’s stock valued at $55,000 after acquiring an additional 1,600 shares during the last quarter. Assetmark Inc. boosted its holdings in Collegium Pharmaceutical by 25.5% in the fourth quarter. Assetmark Inc. now owns 5,445 shares of the specialty pharmaceutical company’s stock valued at $168,000 after acquiring an additional 1,108 shares during the last quarter. Finally, Sheaff Brock Investment Advisors LLC bought a new position in shares of Collegium Pharmaceutical during the 1st quarter worth approximately $204,000.

Insider Activity at Collegium Pharmaceutical

In related news, EVP Shirley R. Kuhlmann sold 19,248 shares of the stock in a transaction on Thursday, September 5th. The stock was sold at an average price of $38.30, for a total value of $737,198.40. Following the completion of the sale, the executive vice president now directly owns 120,161 shares of the company’s stock, valued at approximately $4,602,166.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 3.98% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the company. StockNews.com cut Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 31st. Truist Financial increased their price target on Collegium Pharmaceutical from $40.00 to $42.00 and gave the stock a “buy” rating in a report on Friday, August 9th. Piper Sandler restated a “neutral” rating and set a $37.00 price target (down from $39.00) on shares of Collegium Pharmaceutical in a report on Friday, August 9th. Needham & Company LLC restated a “hold” rating on shares of Collegium Pharmaceutical in a report on Friday, August 9th. Finally, Jefferies Financial Group upgraded Collegium Pharmaceutical from a “hold” rating to a “buy” rating and increased their price target for the stock from $41.00 to $44.00 in a report on Friday, June 7th. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $42.60.

Collegium Pharmaceutical Price Performance

Shares of COLL opened at $37.50 on Monday. Collegium Pharmaceutical, Inc. has a 12-month low of $20.95 and a 12-month high of $40.95. The business’s fifty day moving average is $35.43 and its 200 day moving average is $35.40. The company has a quick ratio of 1.04, a current ratio of 1.11 and a debt-to-equity ratio of 1.71. The stock has a market cap of $1.21 billion, a P/E ratio of 15.63 and a beta of 0.94.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its earnings results on Thursday, August 8th. The specialty pharmaceutical company reported $1.62 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.40 by $0.22. Collegium Pharmaceutical had a return on equity of 107.62% and a net margin of 17.32%. The company had revenue of $145.28 million for the quarter, compared to analysts’ expectations of $143.94 million. During the same period last year, the business earned $1.13 EPS. Collegium Pharmaceutical’s quarterly revenue was up 7.2% compared to the same quarter last year. Sell-side analysts anticipate that Collegium Pharmaceutical, Inc. will post 5.82 earnings per share for the current fiscal year.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.